TriangleAxicabtagene Ciloleucel (NCT05633615)
Axicabtagene Ciloleucel trial for Diffuse Large B-Cell Lymphoma (NCT05633615). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with eligible relapsed or refractory large B-cell lymphoma or grade 3B follicular lymphoma, registering before lymphodepleting chemotherapy and commercial CD19 CAR-T treatment.
The idea: patients with partial response or stable disease around day 30 are randomized to mosunetuzumab, polatuzumab vedotin, both, or observation. Mosunetuzumab links T-cells to CD20-bearing cells; polatuzumab delivers a cell-division-blocking payload to CD79B-bearing cells. Researchers compare time without progression. Observation patients who progress within twelve months may cross over to both drugs.
This phase 2 study plans 396 patients. SWOG sponsors 89 recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.